Asthma diagnosis and treatmentEfficacy and tolerability of antiasthma herbal medicine intervention in adult patients with moderate-severe allergic asthma
Section snippets
Patients
A randomized, double-blind, placebo-controlled study was performed at Weifang Asthma Hospital from September 2003 to September 2004. Weifang Asthma Hospital is a chronic asthma treatment facility receiving patients nationwide. The 4-week study was conducted in the inpatient unit. The recruiting process involved 3 screening steps: clinical history, clinical testing, and laboratory testing. Patients prescreened and recruited from the outpatient facility were admitted to the hospital for purposes
Patient characteristics
One patient in the ASHMI group acquired an infection in the fourth week of treatment and dropped out of the study. Forty-five patients in the ASHMI group and 46 patients in the prednisone group completed the study. There were no significant differences between the 2 groups in age, sex, asthma duration, or body weight before treatment. The baseline FEV1, PEF measurements, symptom scores, and use of β2-agonist in the 2 groups were not different (Table I).
Effect of ASHMI treatment on pulmonary function, symptom scores, and β2-agonist use
By week 4 (the last week of treatment),
Discussion
In this study, we found that ASHMI significantly reduced symptom scores, increased lung function as determined by increased FEV1 and PEF, reduced use of β2-agonist, and reduced peripheral blood eosinophil numbers and serum IgE levels. Although the improvement in FEV1 levels and PEF in the ASHMI-treated group was slightly but significantly less than in the prednisone-treated group, reduction in use of β2-agonist, eosinophil counts, and serum IgE levels was comparable with the prednisone-treated
References (46)
- et al.
Asthma: future directions
Med Clin North Am
(2002) - et al.
The chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma
J Allergy Clin Immunol
(2000) - et al.
Immunomodulatory effect of the anti-asthma Chinese herbal formula, MSSM-002 on Th2 cells
J Allergy Clin Immunol
(2004) - et al.
The potential use of Chinese herbal medicines in treating allergic asthma
Ann Allergy Asthma Immunol
(2004) - et al.
Toxicity grading systems: a comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting
Ann Oncol
(1994) - et al.
Distribution of IgE in a community population sample: correlations with age, sex, and allergen skin test reactivity
J Allergy Clin Immunol
(1981) - et al.
Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma
Clin Ther
(1999) - et al.
Hypothalamic-pituitary-adrenal axis suppression after short-term, high-dose glucocorticoid therapy in children with asthma
J Allergy Clin Immunol
(1986) Rhinitis and asthma: evidence for respiratory system integration
J Allergy Clin Immunol
(2003)- et al.
Epidemiologic evidence for asthma and rhinitis comorbidity
J Allergy Clin Immunol
(2000)
Corticosteroid effect on immunoglobulins
J Allergy Clin Immunol
Mechanisms of asthma
J Allergy Clin Immunol
The role of T lymphocytes in the pathogenesis of asthma
J Allergy Clin Immunol
Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report
J Allergy Clin Immunol
Sepsis associated with immunosuppressive medications: an evidence-based review
Crit Care Med
Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate
Pediatrics
Side-effects of fluticasone in asthmatic children: no effects after dose reduction
Eur Respir J
Introduction
Therapeutic effects of the Chinese herbal formula, MSSM-03d, on persistent airway hyperreactivity and airway remodeling
J Allergy Clin Immunol
Cited by (151)
The great potential of polysaccharides from natural resources in the treatment of asthma: A review
2024, International Journal of Biological MacromoleculesResearch hotspot and frontier analysis of traditional Chinese medicine in asthma using bibliometric methods from 1991 to 2021
2022, Journal of Allergy and Clinical Immunology: GlobalAntispasmodic activity of the ethanol extract of Citrullus lanatus seeds: Justifying ethnomedicinal use in Pakistan to treat asthma and diarrhea
2022, Journal of EthnopharmacologyCitation Excerpt :In recent years, Ayurveda and Chinese medicine have gained popularity as alternative therapeutic options for complex illnesses (Wahid et al., 2020). Common traditional Chinese herbs used in the treatment of asthma include Ma huang, magnolia, Bupleurum, ginkgo, ginseng, P. zizyphi, Huang qin (Hon et al., 2015; Wen et al., 2005). In polytherapy, Ding Chuan Tang, Yu Ping Feng Shan, and Mai-Men-Dong-Tang.
A narrative review of clinical studies of herbal treatment of difficult to manage asthma
2021, Complementary Therapies in Clinical PracticeCitation Excerpt :However, in patients with severe asthma, corticosteroids are often ineffective at controlling airway inflammation, symptoms, and exacerbations [2]. In patients with severe asthma, corticosteroids are used at the high doses required to partially control symptoms, at high doses they are commonly associated with significant side effects including mood instability, weight gain, impaired glycaemic control (glucose intolerance, type 2 diabetes), adrenal suppression and growth retardation in children [3–5]. Additional treatment regimens in Western medicine now include biological therapies [6].
Supported by National Institutes of Health grant # AT001495-01A1.
Disclosure of potential conflict of interest: M.-C. Wen has filed a US patent application (reference #60554775). H. Sampson has received grants/research support from the National Institutes of Health and has filed a US patent application (reference #60554775). M. Kaltan is on the speakers' bureau for AstraZeneca. X.-M. Li has received grants/research support from the National Institutes of Health and has filed a US patent application (reference #60554775).